VCU Massey Cancer Center | Strategic Alliance Partners

July 29, 2024

The panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.

July 29, 2024

Focusing on the selection of subsequent therapies for patients with HER2-low/HER2+ metastatic breast cancer, the panel discusses treatment sequencing considerations and practices.

July 22, 2024

Breast cancer specialists discuss adverse events associated with T-DXd, focusing on monitoring for interstitial lung disease (ILD) and the role of re-challenging patients with T-DXd after resolution of grade 1 ILD.

July 22, 2024

Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions.

July 15, 2024

Ian Krop, MD, PhD, provides an overview of HER2-low and HER2 ultra-low breast cancer and discusses challenges encountered during diagnosis.

July 15, 2024

Experts on breast cancer discuss the potential impact of ongoing research in HER2+ breast cancer, highlighting how results from the DESTINY-Breast07 study may translate to DESTINY-Breast09.

July 08, 2024

Melinda Telli, MD, provides an overview of ongoing research in HER2+ metastatic breast cancer, highlighting the DESTINY-Breast09, PATINA, INAVO122, and HER2CLIMB-05 studies.

July 08, 2024

The panel provides comprehensive insights on approaching first-line treatment of patients with HER2+ metastatic breast cancer and the role of neratinib.

July 01, 2024

Breast cancer specialists outline their institution’s practices regarding the choice between subcutaneous fixed-dose pertuzumab – trastuzumab-hyaluronidase and intravenous pertuzumab and trastuzumab.

July 01, 2024

Kandace P. McGuire, MD, provides clinical insights on how patient monitoring practices inform discussions around surgical options, providing the potential for deescalating surgical management.

June 24, 2024

Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer, and Melinda Telli, MD, discusses the role of surgery.

June 24, 2024

A panel of experts on breast cancer provide insights on challenges encountered during the diagnosis of HER2+ early breast cancer and discuss the role of immunohistochemistry and FISH testing.

March 07, 2024

Survivors of childhood cancer are at a significantly higher risk of death following a major cardiovascular event than the general public.

February 27, 2024

Three Virginia health systems together will serve as one of eight groups in the U.S. to conduct research for the Cancer Screening Research Network.

June 08, 2023

VCU Massey Cancer Center has been designated a Comprehensive Cancer Center by the National Cancer Institute, the nation’s principal authority on cancer research and training.

July 20, 2021

Homogeneous trials present a missed opportunity to discover treatments that might be highly successful in a particular subset of patients.

November 17, 2020

Leslie M. Randall, MD, MAS, ​discusses the unmet need​s in platinum-resistant ovarian cancer.

September 19, 2019

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses ongoing challenges in the management of patients with metastatic HER2-positive breast cancer.

January 29, 2019

Charles E. Geyer, Jrm, MD, discusses the clinical implications of the KATHERINE trial and the outlook for T-DM1 in patients with HER2-positive breast cancer.

January 22, 2019

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses the impact of targeted agents in HER2-positive breast cancer.